Compare Franklin Resources, Inc. (BEN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin Resources, Inc. vs Sana Biotechnology Inc — how do they compare? Franklin Resources, Inc. trades at $33.62 (market cap $16.95B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Franklin Resources, Inc. is far larger — about 15× Sana Biotechnology Inc's market cap, and Franklin Resources, Inc. pays a 3.96% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BEN | SANA | |
|---|---|---|
Market Cap | $16.95B | $1.13B |
Sector | Financials | Health |
52-Week High | $35.77 | $5.92 |
52-Week Low | $21.18 | $2.68 |
Enterprise Value | $29.90B | $1.05B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franklin Resources (BEN) trades at $33.56, up 0.12% on the day, with a bullish technical signal and consistent earnings beats. The company reported record AUM of $1.80 trillion as of July 31, 2026, driven by strong inflows and diversification efforts. Valuation ratios include a P/E of 22.69 and P/S of 1.85, while profitability shows a net income margin of 8.72%.
The outlook is positive with analyst consensus price target of $36.50, though risks include volatile cash flows and competitive pressures. Upside potential hinges on sustained AUM growth and margin expansion, while investor sentiment is mixed with 59% hold ratings amid recent institutional selling.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
